Lv31
342 积分 2021-06-03 加入
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial
5小时前
已完结
Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial
2天前
已完结
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
2天前
已完结
A single ascending‐dose study of muscle regulator ace‐031 in healthy volunteers
2天前
已完结
Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis
2天前
已完结
Targeting ALK1 to block LDL transcytosis and halt atherosclerosis
11天前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
11天前
已完结
Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling
20天前
已完结
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment
21天前
已完结
Dual-epitope targeting of TSLP to simultaneously block TSLPR and IL-7Rα with a Biparatopic nanobody
26天前
已完结
皖公网安备34019202002308
